A multicenter, randomized, open label study to evaluate the lipid lowering efficacy and safety of Vytorin [ezetimibe/simvastatin] 10/20 vs. atorvastatin 10mg in hypercholesterolemia patients with metabolic syndrome in Korea

Trial Profile

A multicenter, randomized, open label study to evaluate the lipid lowering efficacy and safety of Vytorin [ezetimibe/simvastatin] 10/20 vs. atorvastatin 10mg in hypercholesterolemia patients with metabolic syndrome in Korea

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Atorvastatin; Ezetimibe/simvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 17 Dec 2009 Actual patient number changed from 260 to 256 as reported by ClinicalTrials.gov.
    • 26 Sep 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Actual patient number (260) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top